About: A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 13 September 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2007 (uk) article scientifique publié en 2007 (fr) im September 2007 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 13 September 2007 (en) artículu científicu espublizáu en setiembre de 2007 (ast)
publication date	wds:Q57579980-84146180-3917-4817-A684-D2BA9CBAC032
publication date	2007-09-13 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57579980-047FE300-0E23-40D0-A02C-BCE8CE7C6D86
language of work or name	English
exact match	wds:Q57579980-B1EA4157-D68E-42EC-AD21-04FD212E2407
exact match	https://scigraph.springernature.com/pub.10.1007/s10549-007-9726-1
cites work	wds:Q57579980-982701AA-E340-46F9-90A1-EED7B88BFE1A
cites work	Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
author name string	wds:Q57579980-1CBB01B9-6770-471A-A2DE-7FCC8881BCA5 wds:Q57579980-453442AB-B595-418F-A041-D7839676A32E wds:Q57579980-687507A6-8A09-48DD-B637-CED0A528ED4E wds:Q57579980-71295E23-08FC-4AC5-9D2E-14ED7CE75E9E wds:Q57579980-7402BCD6-2942-4593-837B-1B8C7FE7B229 wds:Q57579980-905B6A80-1506-4869-A5FB-10DF2003D7DF wds:Q57579980-90C83C6A-B00B-47A3-AE1F-A044785BE2A9 wds:Q57579980-A4651D3A-3228-4958-B44B-BEAE889DDA24 wds:Q57579980-B6A62751-CBB7-44BA-91E6-95042910F32D wds:Q57579980-EC528656-BD69-47E0-AF3E-2E19C4F29462
author name string	Stephen R D Johnston Gilles Romieu David J Dodwell Dominique Spaeth Youn C Park Angela J Howes Annick Bessems George M Manikhas Juan J Perez Ruixo Peter M De Porre
rdfs:label	A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy (en) A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy (nl)
skos:prefLabel	A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy (en) A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy (nl)
name	A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy (en) A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy (nl)
author	wds:Q57579980-3E1CC639-1F1D-43C4-B716-C4F68E7A6E03 wds:Q57579980-56C1FADC-68D4-49C4-8599-999639EE4DE0 wds:Q57579980-C9C13B20-31E8-4281-B1F9-A4A1C67D7DEB
author	Vladimir Semiglazov Patrick Neven Andrew M. Wardley
title	wds:Q57579980-6CE630D9-C392-4CD4-954B-1E7B31EB36D4
title	A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy (en)
page(s)	wds:Q57579980-88D05A45-B5DC-4E5A-AE83-6678DA8AB337
page(s)	327-335
instance of	wds:Q57579980-F7F41A53-E4CD-4B90-A93E-BBF43F2933A1
instance of	scholarly article
PubMed ID	wds:Q57579980-29D8C29E-1D37-48A0-8445-09AD608AC3C2
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17851757
PubMed ID	17851757
published in	wds:Q57579980-5C65571D-0869-48AB-95D7-8526C9AAAD24
published in	Breast Cancer Research and Treatment
issue	wds:Q57579980-B26E5231-E841-443D-85C5-CAE40D39622E
volume	wds:Q57579980-B718F58B-8BCC-4C0E-8149-358A67049789
issue	2
volume	110
DOI	wds:Q57579980-3C966149-2476-4C9E-9678-C23181675FC8
DOI	http://dx.doi.org/10.1007/S10549-007-9726-1
DOI	10.1007/S10549-007-9726-1
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57579980
is cites work of	Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies Tamoxifen resistance in breast cancer Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. Novel targeted agents for the treatment of advanced breast cancer Biological mechanisms and clinical implications of endocrine resistance in breast cancer Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? Mechanisms of resistance to hormonal treatment in breast cancer Emerging targeted combinations in the management of breast cancer Emerging ways to treat breast cancer: will promises be met?
is cites work of	wds:Q26862550-A93BBE06-D337-49CC-A189-C9B756497FD4 wds:Q37631514-71C837AE-A315-433A-937F-95C969414B9C wds:Q37750046-8C2290CF-3B0F-42D1-82D9-4CF03379910C wds:Q37224555-1C91ACCF-B2C3-4FBB-9B5A-9BA29B5FB022 wds:Q34758477-1FC3A2AE-EA78-4BE5-A799-1B1A688AF5CA wds:Q37570653-37386AA7-3E05-44D3-967A-FEB9F5F2B60B wds:Q37045065-8363A641-9D64-4521-972E-6A5F4D30C43A wds:Q37947909-F64A4935-C60F-4F89-9EED-63749B816DEB wds:Q37593371-B5EA2AFA-FB4A-4450-B540-98F6F7F5F90D wds:Q36458731-F55315F6-8407-46B6-A305-DEA4FD64FE9D wds:Q36132957-EDE93B48-D1CC-4FC2-807B-7F8B168C883D wds:Q37441525-EB0DFED9-E632-4770-A8B0-615264458F40 wds:Q36574547-7D8DC240-BD6D-454E-ACC3-73B83CC234CF wds:Q57105553-FB6EE03A-1BDA-4DA5-B95E-4FC80930CEFC wds:Q38008723-F03B9993-227A-457D-8E15-8EA8F0FC53EA wds:Q37140318-CCE15C83-5C72-439D-9EA8-A6AED1B3059F

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software